← Back to Search

Proton Pump Inhibitor

Dermaprazole Cream for Radiation Dermatitis

Phase 2
Waitlist Available
Led By Shraddha Dalwadi, MD
Research Sponsored by Mohamad Hassan Fakhreddine
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients with head and neck malignancy (including radiation therapy to primary head cancers of any histology and/or neck lymphatics, excluding brain malignancies)
Planned to receive definitive chemoradiation of at least 66Gy
Must not have
Neoadjuvant chemotherapy
Prior head and neck radiotherapy
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 15 months
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a new cream called Dermaprazole on patients with head and neck cancer. The cream is a special version of a medicine that usually reduces stomach acid. Researchers want to see if it is safe and effective for these patients.

Who is the study for?
This trial is for adults over 18 with head and neck cancer, excluding brain malignancies, who are set to receive at least 66Gy of chemoradiation. They should have a performance status that allows daily activities (ECOG 0-2) and no prior treatments like head and neck radiotherapy or neoadjuvant chemotherapy. Those taking proton pump inhibitors must stop with their doctor's approval.
What is being tested?
The study tests Dermaprazole cream against Aquaphor in preventing radiation dermatitis during cancer treatment. It aims to see if the reformulated proton pump inhibitor cream is safe and effective for patients undergoing definitive chemoradiation therapy for head and neck cancers.
What are the potential side effects?
While specific side effects of Dermaprazole aren't detailed here, similar creams may cause skin reactions such as redness, itching, or rash. Patients might also experience typical side effects from radiation like dryness or peeling skin.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have a cancer in my head or neck area, but not in my brain.
Select...
I am scheduled for a specific cancer treatment with radiation.
Select...
I have a confirmed diagnosis of head and neck cancer from a biopsy.
Select...
I can take care of myself and am up and about more than half of my waking hours.
Select...
I am 18 years old or older.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have received chemotherapy before surgery.
Select...
I have had radiotherapy for head or neck cancer.
Select...
I am not currently receiving chemotherapy.
Select...
I have an open wound.
Select...
I have an autoimmune or skin condition that might react to radiation.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~15 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 15 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Rates of clinically significant radiation dermatitis as defined as NCI CTCAE version 5 grade 2 or higher

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: DermaprazoleExperimental Treatment1 Intervention
30 HNC patients who will be using Dermaprazole twice daily for 7 weeks
Group II: AquaphorActive Control1 Intervention
15 HNC patients using Aquaphor, the current clinical standard of care
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Dermaprazole
2022
Completed Phase 2
~10

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for Head and Neck Cancers (HNC) include surgery, radiation therapy, chemotherapy, and targeted therapies. Surgery physically removes the tumor, aiming for complete resection while preserving function. Radiation therapy uses high-energy rays to kill cancer cells, often employed to control local-regional disease. Chemotherapy involves cytotoxic drugs that target rapidly dividing cells, used alone or in combination with other treatments. Targeted therapies, such as cetuximab, inhibit specific molecular pathways critical for cancer cell survival and proliferation. These treatments are crucial for HNC patients as they aim to eradicate cancer while preserving essential functions like swallowing and salivation. Dermaprazole, a proton pump inhibitor cream under investigation, may offer a novel approach to managing radiation dermatitis, a common side effect of radiation therapy, potentially improving patient comfort and treatment adherence.
ACR Appropriateness Criteria: local-regional therapy for resectable oropharyngeal squamous cell carcinomas.

Find a Location

Who is running the clinical trial?

Mohamad Hassan FakhreddineLead Sponsor
The University of Texas Health Science Center at San AntonioLead Sponsor
476 Previous Clinical Trials
92,913 Total Patients Enrolled
Shraddha Dalwadi, MDPrincipal InvestigatorThe University of Texas Health Science Center - Mays Cancer Center

Media Library

Dermaprazole Cream (Proton Pump Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT04865731 — Phase 2
Dermaprazole Cream (Proton Pump Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04865731 — Phase 2
Head and Neck Cancers Clinical Trial 2023: Dermaprazole Cream Highlights & Side Effects. Trial Name: NCT04865731 — Phase 2
Head and Neck Cancers Research Study Groups: Dermaprazole, Aquaphor
~2 spots leftby Dec 2025